| |
April 3 - 4, 2023 | San Diego, CA Connect with leading communications professionals and have honest, open discussions about how to develop your career in the industry. Register Now!
|
|
| By Nick Paul Taylor,Gabrielle Masson Sanofi's head of global R&D John Reed, M.D., Ph.D., has departed for a spot at Johnson & Johnson, where he'll serve as executive vice president of pharmaceutical R&D. |
|
|
|
By Kevin Dunleavy Twenty-two months after European Commission President Ursula von der Leyen admitted to The New York Times that she negotiated a COVID-19 vaccine deal with Pfizer CEO Albert Bourla, Ph.D., through text messages, the newspaper is suing the commission over its refusal to make the texts public. While the lawsuit was filed on Jan. 25 and listed on the European Court of Justice’s public website on Monday, none of the documents related to the case are available to the public. Two people familiar with the suit confirmed it to Politico. |
By Andrea Park Even as Philips nears the end of the repair-and-replace program for its recall of 5.5 million respiratory devices, complaints about the machines are still rolling in. |
By Eric Sagonowsky Facing tens of thousands of lawsuits over cancer risks on the popular heartburn drug Zantac, GSK has argued there's "no consistent or reliable evidence" that the medicine causes any cancer. But a new report in Bloomberg Businessweek says GSK's own scientists have long known about the risks. |
|
Tuesday, March 14, 2023 | 2pm ET / 11am PT Join this webinarto hear industry experts across the clinical research space share their perspectives on inefficiencies in the current clinical research space, how to prioritize change, where to begin, how to measure success, and considerations when evaluating and selecting enabling technology. Register now.
|
|
By Max Bayer Sorrento Therapeutics is filing for bankruptcy amid ongoing litigation against billionaire Patrick Soon-Shiong and his company NantCell. |
By Teresa Carey This week on "The Top Line," we discuss the intense patent fight between Moderna and Pfizer-BioNTech around the mRNA technology used in their COVID-19 vaccines. We also talk about negotiating vaccine contracts via text messages, one of the biggest medtech deals of the year and other top headlines from this week. |
By Ben Adams As Pfizer looks to shore up falling Paxlovid sales this year, it has launched its first commercial for the COVID therapy that goes hard on branding. |
By Gabrielle Masson Several biotech entrepreneurs have launched a new venture capital vehicle dubbed Curie.bio that will serve not only as a seed investor, but as a drug discovery co-pilot for founders. |
By Fraiser Kansteiner In the patent feud over rival PCSK9 inhibitors Praluent and Repatha, Amgen isn’t the only pharma with friends in high places. |
By Max Bayer Hours after Arrowhead Pharmaceuticals revealed that Johnson & Johnson is returning a clinical-stage NASH asset “out of the blue," CEO Chris Anzalone says that the entire $3.7 billion collaboration between the two is done. |
By Max Bayer GSK's head of vaccine R&D, Phil Dormitzer, is confident that the company has posted pack-leading data for its RSV vaccine, as it nears the finish line of the regulatory race. But he wouldn't commit to restarting trials testing the shot in maternal women after a phase 3 study was halted a year ago. |
By Andrea Park Medtronic was found guilty this week of infringing on a patent concerning transcatheter aortic valve replacement systems that was awarded to Colibri Heart Valve in 2014. |
By Zoey Becker In the latest FDA ding on India's Sun Pharma, the agency pulled 34,000 bottles of generic diltiazem hydrochloride after the pills failed impurity specification and dissolution testing at an FDA lab. |
By Joseph Keenan Labcorp has its sight set on spinning off its CRO segment by midyear, and, now, the independently trading company's name has been revealed as Fortrea. |
Fierce podcastsDon't miss an episode |
| This week on "The Top Line," we discuss the intense patent fight between Moderna and Pfizer-BioNTech around the mRNA technology used in their COVID-19 vaccines. We also talk about negotiating vaccine contracts via text messages, one of the biggest medtech deals of the year and other top headlines from this week. |
|
|---|
|
|
|
Monday, March 20, 2023 | 2pm ET / 11am PT In this webinarwe will discuss balancing cost considerations with other factors of importance including production volume, dosage form, regulatory considerations, the geography in which the product will launch, dual sourcing to mitigate risk, building robust supply chains with the capacity to handle disruption, supplier qualification, and more. Register now.
|
|
| ResearchLike many top 10 and global pharma companies, an H1 client needed to diversify both its patient outreach and site investigator profiles for upcoming trials. Sponsored by: H1 |
| Whitepaper Discover the Power of Small with NanoplasmidTM – the next-generation plasmid for manufacturing today’s cell and gene therapies. Sponsored by: Aldevron |
| WhitepaperThis paper explores the cost drivers behind gene therapies and how they are likely to evolve in the coming years. Sponsored by: Blue Matter |
| WhitepaperExploring the biology of G Protein-Coupled Receptors (GPCRs) and outlining a novel approach for developing therapeutics against previously undruggable GPCRs Sponsored by: Orion Biotechnology |
| Whitepaper Learn more about critical success factors for your next launch based on the experience of 100+ pharma product launches. Sponsored by: Herspiegel Consulting |
| Whitepaper What makes nucleotides suitable for current good manufacturing practices? Sponsored by: Thermo Fisher Scientific |
| WhitepaperAccelerating bioproduction towards high performance and scale Sponsored by: Capgemini Americas Inc. |
| eBook Catalent’s Carla Vozone discusses the significant trends in the Orally Inhaled & Nasal Drug Delivery (OINDP) segment including large molecules and novel indications. Sponsored By: Catalent |
| Research Learn more on Catalent’s step-wise approach for the definition and execution of Process Characterization for the production of a monoclonal antibody for late phase process characterization and development. Sponsored by: Catalent |
| WhitepaperLearn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region. Sponsored by: Catalent |
| Research Learn more on an approach for process characterization for the production of a monoclonal antibody, which will improve the efficiency and effectiveness of the process by targeting the right design and number of experiments. Sponsored by: Catalent |
| WhitepaperExplore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world. Sponsored by: Catalent |
| Case Study Learn more on an approach for process characterization for the production of a monoclonal antibody, which will improve the efficiency and effectiveness of the process by targeting the right design and number of experiments. Sponsored by: Catalent |
| |
|
